UBS sets USD 94 target for Viking Therapeutics stock

Published on 10/20/2026 at 13:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viking starts two oral SUNRISE studies of 560 adults over 68 weeks. Viking Therapeutics stock costs EUR 22.38 on October 20, 2026 before October 28 results.

Oral trials and analyst coverage

UBS initiated coverage with a USD 94 target on October 14, 2026.
The SUNRISE program targets 560 adults per study over 68 weeks.
Viking Therapeutics stock traded at EUR 22.38 at 1:20 p.m. CEST at Lang & Schwarz on October 20, 2026.

VKTX, US92686J1060, Illustration mit AI erstellt.

UBS initiated coverage of Viking Therapeutics with a Buy rating and a USD 94 price target on October 14, 2026, according to Business Insider. The same date brought Viking's launch of the oral VK2735 Phase 3 program, making trial execution the central issue for Viking Therapeutics stock.

Oral trials add a major test

Viking's SUNRISE-1 and SUNRISE-2 studies each target 560 adults and will measure percentage change in body weight after 68 weeks. The trials cover adults with obesity, including a separate study for participants with type 2 diabetes, and evaluate daily doses of 27.5 milligrams, 35 milligrams and 55 milligrams against placebo, according to the company's October 14, 2026 release from Viking Therapeutics. The company is also running two Phase 3 studies of subcutaneous VK2735, with one enrolling approximately 4,500 adults and the other approximately 1,000 adults.

What does the cash position mean?

The financial base is substantial but expensive to deploy. Viking reported a second-quarter 2026 net loss of USD 128.1 million, or USD 1.10 per share, versus USD 65.6 million, or USD 0.58 per share, in the second quarter of 2025. The company held USD 502.0 million in cash and short-term investments on June 30, 2026, compared with USD 706.0 million on December 31, 2025, according to the second-quarter earnings-call transcript published by Yahoo Finance. Research and development spending reached USD 115.8 million in the quarter, versus USD 60.2 million a year earlier.

Three milestones shape the story

On September 28, 2026, Viking announced the closing of two financing offerings, comprising common stock and convertible senior notes. On October 6, 2026, it announced a Phase 3 oral maintenance dosing trial. On October 14, 2026, the company started the oral Phase 3 program with two 560-patient studies. This sequence moves VK2735 from financing and maintenance work toward larger efficacy tests.

Dates that matter next

Viking's next scheduled reporting date is October 28, 2026, for third-quarter results after the market closes. The company also expects the 68-week SUNRISE studies to provide their primary endpoint assessment after the treatment period.

Stock trades below its Nasdaq range

For investors, the next test combines clinical execution with cash use. The primary-market quote stood at USD 25.05 on October 19, 2026, with a 52-week range of USD 24.94 to USD 43.15 and a market capitalization of USD 3.2 billion. The reference euro quote was trading at EUR 22.38 at Lang & Schwarz on October 20, 2026 at 1:20 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Viking Therapeutics stock.